Key EventCipla signs exclusive licensing deal for TQB2102 ADC with SBP Group
ImpactThis partnership expands Ciplaβs oncology pipeline with a high-potential ADC, potentially driving future growth in emerging markets.Sign up to read impact
Key EventUSFDA classifies Invagen facility inspection as Voluntary Action Indicated
ImpactThe VAI classification signals minor regulatory deviations requiring follow-up but does not indicate product recalls or supply disruptions.Sign up to read impact